Compare HCAI & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAI | BRTX |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.3M |
| IPO Year | N/A | 2015 |
| Metric | HCAI | BRTX |
|---|---|---|
| Price | $7.15 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.8M | 1.3M |
| Earning Date | 05-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.19 |
| 52 Week High | $10.60 | $2.04 |
| Indicator | HCAI | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 39.40 |
| Support Level | $0.41 | $0.23 |
| Resistance Level | $8.75 | $0.32 |
| Average True Range (ATR) | 1.10 | 0.02 |
| MACD | 0.44 | 0.00 |
| Stochastic Oscillator | 69.71 | 39.47 |
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.